Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

Cash, cash equivalent and marketable securities were $20.8 million as of December 31, 2025, compared to $10.4M as of December 31, 2024. “We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without a GBA1 mutation. The promising impact GT-02287 has on the causative biology of Parkinson’s disease has been further elucidated from the analysis of functional and biomarker changes from the Phase 1b study,” commented Gene Mack, president and CEO of Gain Therapeutics (GANX).